antibodies ( 
reported the possible transformation of Tg during its secretion. The assay for serum Tg we report here is based on meeting these three criteria. First, the lower detection limit of the new TG IRMA Pasteur, which we developed by using five anti-Tg monoclonal antibodies (MAbs) directed against domains I, ffi, and VI of human Tg, has been markedly improved.
The new detection limit is 0.2 g/L, compared with the 3 j.LgfL previously reported [6] . Second, the interference by thyroid diseaseassociated aAbs has been considerably reduced by the use o selected MAbs directed against three antigenic domains of Tg (domains I, III, \TI) that are not recognized by these aAbs. Indeed, our previous studies have pointed out the existence of at least 11 epitopic domains on the Tg molecule [7, 8] The labeled MAb can be stored without loss of activity for 7 weeks at 4 #{176}C.
Preparation of coated tubes. MAbs 2, 4, 5, and 13, in a ratio of 1/3/1/1, were diluted in phosphate-buffered saline (Seromed, Biochrom, Berlin, Germany) at a total final concentration of 20 mg/L. Then 500 L of this solution was incubated overnight at room temperature in polystyrene tubes (Startubes; NUNC, Roskilde, Denmark).
The coating solution was then removed and the tubes were filled with 2 mL of phosphate-buffered saline containing 3 g/L bovine serum albumin and 50 gIL sucrose. er 15 mm at room temperature, the saturation solution was emoved and the tubes were dried under reduced pressure.
g. We used human Tg (UCB-Bioproduct, Liege, Belgium) urifled from human thyroid glands. Although the iodine conent varies from batch to batch (2 to 15 g/kg), no immunological ifferences were observed with the different lots used. The Tg sed as calibrator was diluted in the assay buffer. The other blood amples (serum and plasma) were obtained from patients with thyroid pathologies (Hashimoto thyroiditis, Grave disease, or differentiated thyroid carcinoma). We used only blood specimens that were sent for routine biochemical investigations; thus, no additional blood was drawn from patients solely for the purpose of this study. then plotted with these data.
Results
Calibration curve. As shown in Fig. 1 , the amount of radioactivity bound to the coated tubes is directly proportional to the amount of Tg. The signal (counts/minute) varied linearly with Tg concentration between 0.2 and 500 g/L.
Detection limit. Defined as the confidence limit at 95% for the zero standard (i.e., mean + 2 SD), the detection limit is 0.2 g/L from the beginning to the end of the tracer's life.
Reproducibility.
Reproducibility was evaluated by 10 measurements of 10 sera distributed in the range of linearity of the assay, with either one (intraassay reproducibility) or several lots (in- Dilution tests performed on sera with very high Tg concentrations (up to l0' jg/L) did not show a hook effect (data not shown). and the ELSA-HTG assay ( Fig. 2A) . The correlation with the RIA Tg assay was similar (Fig. 2B ), but the slope of the linear regression curve was different (y = O.71x -3.9, P <0.001).
Effect of aAbs.
To validate the reality of minimized interference by aAbs, we carried out recovery studies on sera both with and without aAbs, first on a smaller number of samples and then on a more extended population.
First, 644 samples were studied (283 samples without aAbs and 361 with aAbs). The spread of the recovery percentages for both populations follows a gaussian distribution centered around the 100% value (Fig. 3A) . Three samples (0.5%) among the 611 did not fall within this distribution range. These samples, which had a very high concentrations of aAbs (>5000 kIU/L), gave a Tg value of 0 ig/L in our assay and in other MAb-based IRMA kits also. The recovery, whether aAbs were present or not, ranged from 50% to 150%. Both profiles, with and without aAbs, are regular and symmetric, with average values of 94% ± 17% and 96% ± 12%, respectively, and do not differ significantly, as verified with the bioequivalence test. This test allowed us to discard the nonequivalence hypothesis with a limit of 6% at a confidence value of 95%. The study of the recovery percentage was extended to a population of 2759 samples with or without aAbs (Fig. 3B) . The results confirm the previous data. The percentage spread of recovery shows the same profile, with values ranging from 0% to 176% (mean ± SD, 99% ± 13%). Forty-five samples (1.6% of the total population) gave recovery percentages <70%; of these, 8 did not have aAbs.
ROC analysis and determination of the cutoff value. Using our new assay and the two commercialized
MAb IRMA kits, we assayed 108 sera from patients treated for differentiated thyroid carcinoma by total thyroidectomy.
A total body 1311 scan showed a thyroid remnant for 54 patients. Tg concentrations were measured after withdrawal from T4 treatment. All 108 patients were negative for aAbs. The Tg concentrations determined by our technique ranged from 0 to 3 ig/L for patients without thyroid remnant and from 0.2 to 53 .tg/L for patients with thyroid
remnant. An ROC curve was then constructed (Fig. 4) . The area under the curve (0.891) is significantly different from that obtained with the ELSA-HTG and the RIA Tg kits (0.783 and 0.753, respectively, data not shown). The optimized cutoff value of Tg for the follow-up ol differentiated thyroid carcinoma patients was I g/L-the intercept of the curves for cutoff = f (specificity) and cutoff = (sensitivity). This reflects that the same importance was given to false-negative and false-positive results. Results of the TG IRMA Pasteur assay performed on sera from 57 patients with or without metastases after total thyroidectomy and an ablative dose of 1311
were negative for aAbs. with the RIA Tg kit ( 5.5%).
Several hypotheses can he proposed to explain the persistence of a small percentage of sera with low recovery by the TG IRMA Pasteur assay. Anti-Tg aAbs produced during systemic autoimmune diseases such as lupus erythematosus and primary Sjogren syndrome f17J have an epitopic specificity pattern larger than the aAbs present in autoimmune thyroid disease /lOJ. These aAbs are thus susceptible to interfere with the assay. This was the case for one sample with low recovery. Perhaps other sera used for the recovery test also came from patients with thyroid diseases associated with these pathologies.
Finally, we note that some sera with a low recovery did not contain aAhs. To un(lerstand these results, we performed recovery tests with two other IRMAs (for thyrotropin and follitropin). The recovery obtained for >100 sera for each assay ranged from 50% to 140% (data not shown). This leads us to conclude that (a)this type of spread is not associated exclusively with our Tg IR]'vIA and (b) there is no systematic relation between a recovery <70% and the presence of aAhs. Such results pose the problem of how to choose the threshold for classifying a recovery as low. This value is usually 70%. However, taking into account the range of the recovery for sera without aAbs (Fig. 3A) , perhaps the threshold should he closer to 50%. If so, the percentage of low-recovery sera is 0.6% in our assay. The ROC curve confirms the diagnostic performance of our assay. This observation is strengthened by the results obtained by the follow-UI) of differentiated thyroid carcinoma, which emphasize the high diagnostic precision of the assay: Of patients with metastases, 97% had a Tg concentration above the cutoff value, whereas all patients without detectable scintigraphic thyroid remnants had Tg values below the cutoff.
In conclusion, the combined use of judiciously selected MAbs allowed us to develop an assay for Tg with minimal interference from aAbs and with a very low detection limit (0.2 tg/L). Moreover, the recognition of three cpitopic domains (I, III, VI) on Tg may constitute a better guarantee for the detection of different circulating forms of Tg.
